Cargando…
LINC01001 Promotes Progression of Crizotinib-Resistant NSCLC by Modulating IGF2BP2/MYC Axis
Background: Crizotinib is a microtubule-related protein-4-anaplastic lymphoma kinase (EML4-ALK) multi-target tyrosine kinase inhibitor applied in the treatment of ALK-rearranged NSCLC. However, the specific molecular mechanism underlying its therapeutic effect remains unclear. Therefore, the purpose...
Autores principales: | Zhang, Meiling, Wang, Qian, Ke, Zihao, Liu, Yijing, Guo, Huijin, Fang, Shencun, Lu, Kaihua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8497803/ https://www.ncbi.nlm.nih.gov/pubmed/34630126 http://dx.doi.org/10.3389/fphar.2021.759267 |
Ejemplares similares
-
N6-methyladenosine modified LINC00901 promotes pancreatic cancer progression through IGF2BP2/MYC axis
por: Peng, Wan-Xin, et al.
Publicado: (2022) -
IGF2BP1, a New Target to Overcome Drug Resistance in Melanoma?
por: Xi, Yufeng, et al.
Publicado: (2022) -
Silencing of circCRIM1 Drives IGF2BP1-Mediated NSCLC Immune Evasion
por: Peng, Wenbei, et al.
Publicado: (2023) -
AhR Antagonist Promotes Differentiation of Papillary Thyroid Cancer via Regulating circSH2B3/miR-4640-5P/IGF2BP2 Axis
por: Sa, Ri, et al.
Publicado: (2021) -
Epigenetic silencing of LncRNA LINC00261 promotes c-myc-mediated aerobic glycolysis by regulating miR-222-3p/HIPK2/ERK axis and sequestering IGF2BP1
por: Zhai, Shuyu, et al.
Publicado: (2020)